title: Long-term effects of budesonide on inflammatory status in COPD.
abstract: A beneficial effect of long-term corticosteroid treatment in patients with COPD may be linked to suppressing inflammation, in particular neutrophilic inflammation. Effects on neutrophilic and eosinophilic inflammation and on lung function of long-term inhaled budesonide treatment (800 microg daily, 6 months, double-blind, randomised, cross-over versus placebo) were studied and compared to the effects of 3 weeks oral prednisolone (30 mg daily) in 19 patients with COPD (mean age 63 y, FEV(1) 65% of predicted). Neither treatment influenced neutrophilic inflammation. Inhaled budesonide compared to placebo significantly reduced sputum % eosinophils at 3 months (-42%, p = 0.036), but not significantly at 6 months (-31%, p = 0.78). Eosinophil count per g sputum was decreased with 30% at 3 months (p = 0.09) and with 9% at 6 months (p = 0.78). FEV(1) was slightly higher after 6 months budesonide (+2.5% predicted, p = 0.09). Prednisolone significantly reduced sputum % eosinophils (-87%, p = 0.007), but did not affect eosinophil count per g sputum and did not improve FEV(1) (-0.6% predicted, p = 0.40). A higher baseline FEV(1) (%) correlated with effects of budesonide on FEV(1) (p < 0.001), effects on sputum interleukin-8 and eosinophil cationic protein (both p < 0.05) and tended to correlate with effects on sputum % eosinophils (p = 0.056). Baseline inflammatory data and effects of prednisolone did not correlate with effects of budesonide. Effects of inhaled budesonide in COPD are not restricted to patients with severe disease and may be linked to a suppression of eosinophilic inflammation. Investigating effects of prednisolone has no predictive value for long-term treatment.
authors.affiliation: Department of Pulmonology, Academic Medical Center, University of Amsterdam, Amsterdam, DE, The Netherlands. martin.boorsma@planet.nl
authors.forename: M
authors.initials: M
authors.lastname: Boorsma
authors.forename: R
authors.initials: R
authors.lastname: Lutter
authors.forename: M A
authors.initials: MA
authors.lastname: van de Pol
authors.forename: T A
authors.initials: TA
authors.lastname: Out
authors.forename: H M
authors.initials: HM
authors.lastname: Jansen
authors.forename: R E
authors.initials: RE
authors.lastname: Jonkers
mesh_terms: D000280:Administration, Inhalation; D000284:Administration, Oral; D000368:Aged; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D019819:Budesonide / Q000008:administration & dosage*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004804:Eosinophils / Q000473:pathology; D005260:Female; D005541:Forced Expiratory Volume; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007249:Inflammation; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000473:pathology; D011239:Prednisolone / Q000008:administration & dosage; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013183:Sputum / Q000166:cytology
chemical_list: D001993:Bronchodilator Agents; D005938:Glucocorticoids; D019819:Budesonide; D011239:Prednisolone